Structure Therapeutics Inc.
GPCRNasdaq
$48.48
↑ +5.3%Jul 17 close · end-of-day
Price
1Y↑ +147.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.5B
Enterprise Value
$9.1B
P/E
—
P/S
—
P/B
7.3
EV/EBITDA
—
PEG
—
FCF Yield
-1.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$170.3M
Free Cash Flow (TTM)
-$159.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-11.8%
ROIC
—
Debt / Equity
—
Net Cash
$1.5B
Return 1Y
+148.2%
Company profile
We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. We are a Cayman Islands exempted company incorporated with limited liability. We were initially formed as a Delaware corporation in 2016 under the name ShouTi Inc., and reorganized as a Cayman Islands exempted company in 2019. Our principal executive office is located at 611 Gateway Blvd., Suite 223, South San Francisco, California. The principal executive office of our research and development operations is located at Unit 02, F5, No. 1, Lane 2889, Jinke Road, China (Shanghai) Free Trade Zone, Shanghai, People’s Republic of China, 201203. Our telephone number at this address is 86 21 61215839. Our current registered office in the Cayman Islands is located at the offices of International Corporation Services Ltd., P.O, Box 472, 2nd Floor, Harbour Place, 103 South Church Street, George Town, Grand Cayman.
- CEO
- Raymond Stevens
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- structuretx.com
Management & directors
- Lin XichenCHIEF SCIENTIFIC OFFICER
- Lang MatthewCOO & GC
- Coll Crespo BlasCHIEF MEDICAL OFFICER
- Hall AshleyChief Development Officer
- Ma YingliCHIEF TECHNOLOGY OFFICER
- Stevens Raymond CCHIEF EXECUTIVE OFFICER
- Yoon JunCHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
GPCR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.35↑ +29.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$52.6M | -$102.8M | -$158.2M | -$176.6M |
| Net income | -$51.3M | -$89.6M | -$122.5M | -$141.2M |
| Diluted EPS | -$5.51 | -$0.81 | -$0.78 | -$0.80 |
| Operating cash flow | -$46.1M | -$79.5M | -$116.6M | -$222.2M |
| Free cash flow | -$46.3M | -$81.7M | -$117.9M | -$225.8M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$33.3M | -$45.8M | -$47.1M | -$56.3M | -$70.5M | -$73.8M | $24.0M | -$89.4M |
| Net income | -$26.0M | -$34.0M | -$36.5M | -$46.8M | -$61.7M | -$65.7M | $33.0M | -$76.0M |
| Diluted EPS | -$0.18 | -$0.20 | -$0.21 | -$0.27 | -$0.36 | -$0.37 | $0.20 | -$0.35 |
| Operating cash flow | -$26.4M | -$19.7M | -$36.5M | -$52.2M | -$54.6M | -$51.0M | -$64.4M | $15.2M |
| Free cash flow | -$26.8M | -$20.4M | -$36.5M | -$52.5M | -$54.8M | -$52.6M | -$65.9M | $14.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 24, 2026
Jun 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Lin Xichen· CHIEF SCIENTIFIC OFFICER | Option exercise | 23,634 | $0.34 | $8,035.56 | filing |
| 2026-07-14 | Lin Xichen· CHIEF SCIENTIFIC OFFICER | C | 23,634 | $0.00 | $0.00 | filing |
| 2026-06-25 | Lin Xichen· CHIEF SCIENTIFIC OFFICER | Option exercise | 23,634 | $0.34 | $8,035.56 | filing |
| 2026-06-25 | Lin Xichen· CHIEF SCIENTIFIC OFFICER | C | 23,634 | $0.00 | $0.00 | filing |
| 2026-04-15 | Lang Matthew· COO & GC | Award | 184,614 | $0.00 | $0.00 | filing |
| 2026-03-19 | Hall Ashley· Chief Development Officer | Award | 47,706 | $0.00 | $0.00 | filing |
| 2026-03-19 | Coll Crespo Blas· CHIEF MEDICAL OFFICER | Award | 75,897 | $0.00 | $0.00 | filing |
| 2026-03-19 | Ma Yingli· CHIEF TECHNOLOGY OFFICER | Award | 32,526 | $0.00 | $0.00 | filing |
| 2026-03-19 | Lin Xichen· CHIEF SCIENTIFIC OFFICER | Award | 43,368 | $0.00 | $0.00 | filing |
| 2026-03-19 | Yoon Jun· CHIEF FINANCIAL OFFICER | Award | 104,085 | $0.00 | $0.00 | filing |
| 2026-03-19 | Stevens Raymond C· CHIEF EXECUTIVE OFFICER | Award | 260,217 | $0.00 | $0.00 | filing |
| 2026-03-03 | Stevens Raymond C· CHIEF EXECUTIVE OFFICER | Tax withholding | 53,454 | $20.99 | $1.1M | filing |
| 2026-03-03 | Yoon Jun· CHIEF FINANCIAL OFFICER | Tax withholding | 22,305 | $20.99 | $468,181.95 | filing |
| 2026-03-03 | Lin Xichen· CHIEF SCIENTIFIC OFFICER | Tax withholding | 18,735 | $20.99 | $393,247.65 | filing |
| 2026-03-03 | Coll Crespo Blas· CHIEF MEDICAL OFFICER | Tax withholding | 11,826 | $20.99 | $248,227.74 | filing |
| 2026-03-03 | Ma Yingli· CHIEF TECHNOLOGY OFFICER | Tax withholding | 11,313 | $20.99 | $237,459.87 | filing |
| 2026-03-03 | Hall Ashley· Chief Development Officer | Tax withholding | 4,836 | $20.99 | $101,507.64 | filing |
| 2025-09-18 | Coll Crespo Blas· CHIEF MEDICAL OFFICER | Tax withholding | 8,106 | $7.74 | $62,767.19 | filing |
| 2025-09-18 | Hall Ashley· Chief Development Officer | Tax withholding | 6,021 | $7.74 | $46,622.41 | filing |
| 2025-07-01 | Stevens Raymond C· CHIEF EXECUTIVE OFFICER | Tax withholding | 16,050 | $6.84 | $109,727.43 | filing |
| 2025-07-01 | Lin Xichen· CHIEF SCIENTIFIC OFFICER | Tax withholding | 12,846 | $6.84 | $87,822.96 | filing |
| 2025-07-01 | Yoon Jun· CHIEF FINANCIAL OFFICER | Tax withholding | 7,089 | $6.84 | $48,464.66 | filing |
| 2025-07-01 | Ma Yingli· CHIEF TECHNOLOGY OFFICER | Tax withholding | 4,470 | $6.84 | $30,559.60 | filing |
| 2025-07-01 | Coll Crespo Blas· CHIEF MEDICAL OFFICER | Tax withholding | 1,434 | $6.84 | $9,803.68 | filing |
| 2025-07-01 | Ma Yingli· CHIEF TECHNOLOGY OFFICER | Award | 24,459 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.